ArticleScientific reports2014

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.

Feng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.